Introduction
============

Breast cancer is a heterozygous disease with a strong heritable component, and it is estimated that \~15% of breast cancer cases have at least one affected first-degree relative.[@b1-ott-9-1241] Despite the tremendous advancement gained in medical sciences, to unravel the genetic architecture of breast cancer still remains a challenge. So far, a number of susceptibility genes have been suggested to underlie breast carcinogenesis.[@b2-ott-9-1241],[@b3-ott-9-1241] One of the promising candidate genes is apolipoprotein E (*APOE*) and its expression is proposed as a tumor-associated biomarker.[@b4-ott-9-1241] APOE is a class of apolipoprotein and its primary function is to mediate cholesterol metabolism and catabolize triglyceride-rich lipoprotein constituents. Beyond this well-known function, evidence is amassing to reveal a different role for APOE in carcinogenesis and tumor development.[@b5-ott-9-1241] The gene encoding *APOE* is mainly inherited as one of the three alleles: ε2 (Arg148→Cys), ε3 (Cys112), and ε4 (Cys112→Arg), which generate three homozygous genotypes (ε2/2, ε3/3, and ε4/4) and three heterozygous genotypes (ε2/3, ε2/4, and ε3/4), each with a diverse receptor-binding capacity.[@b6-ott-9-1241] In addition, there are several other minor alleles such as ε5 and ε7 in *APOE* gene; due to the methodological drawbacks of restriction fragment length polymorphism (RFLP), these minor alleles could be easily missed.[@b7-ott-9-1241],[@b8-ott-9-1241] In medical research literature, the ε2, ε3, and ε4 alleles in *APOE* gene are given the most attention, and their susceptibility toward breast cancer risk has been widely evaluated by genetic association studies;[@b9-ott-9-1241]--[@b11-ott-9-1241] however, the results of only a few studies are reproducible. A previous meta-analysis of eight articles by Saadat[@b12-ott-9-1241] found that *APOE* gene ε4 allele or ε4 positive genotypes was exclusively associated with breast cancer in Asians. Further meta-analysis by Anand et al[@b13-ott-9-1241] failed to validate this significant finding for ε4 positive genotypes in overall susceptibility to breast cancer. Besides unavoidable genetic heterogeneity across races and ethnicities, a possible explanation for such divergence is inadequate statistical rigor to quantify the effect size reliably. To obtain a more precise estimate, we conducted an updated systematic review and meta-analysis of previous studies by incorporating additional articles and seeking other potential causes of heterogeneity in both subgroup and meta-regression analyses.

Methods
=======

This systematic review and meta-analysis was conducted based on the guidelines listed in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

Literature retrieval
--------------------

A comprehensive literature search was conducted in the Medline, Embase, and Web of Science electric databases. Key subjects used for retrieval included apolipoprotein E or APOE or APO E and breast cancer or breast carcinoma. The last search was on July 5, 2015. Each retrieved article was reviewed from the title or abstract to definitively exclude the one with irrelevant content. In case of uncertainty, the full text was downloaded for further review. To avoid missing hits, the bibliographies of original articles and reviews were manually searched.

Eligibility appraisal
---------------------

The eligibility of each retrieved article was appraised according to the following criteria: 1) the clinical endpoint must be breast cancer with validated clinical diagnoses; 2) it should be designed as a case--control association study; 3) the genotypes or alleles of *APOE* gene ε2/ε3/ε4 polymorphism or its associated risk estimates -- odds ratio (OR) or beta and its 95% confidence interval (95% CI) or standard error -- should be provided; and 4) conference abstracts or proceedings (due to insufficient necessary information) and non-English articles are not considered. In case of more than one independent study in a single article, each study was summarized and analyzed separately.

Information extraction
----------------------

Relevant information from each eligible article was extracted separately by two authors (Yun-Long Liu and Hao-Min Zhang) according to a predefined table designed by all responsible authors, including authors, the year of publication, race/ethnicity, study design, source of controls, genotyping method, sample size, age, body mass index (BMI), and the genotype or allele counts of *APOE* gene ε2/ε3/ε4 polymorphism or the associated ORs and 95% CIs. In case of unresolved-by-discussion disagreements, a third senior author (Hong-Guang Bao) was involved until a consensus was reached.

Statistical analysis
--------------------

The risk estimate for *APOE* gene ε2/ε3/ε4 polymorphism in susceptibility to breast cancer was expressed as OR and its 95% CI, which were pooled in a random-effects model using the method proposed by DerSimonian and Laird.[@b14-ott-9-1241] The heterogeneity among the results of different studies was weighed by the *I*^2^ statistic, which is defined as the percentage of observed between-study variability that stems from heterogeneity rather than chance. As recommended by Higgins et al, an *I*^2^ statistic of 50% or greater is generally interpreted as significant heterogeneity.[@b15-ott-9-1241] To explore possible causes of heterogeneity, both subgroup and meta-regression analyses were conducted. Publication bias was assessed by the trim-and-fill method and the Egger's test.[@b16-ott-9-1241] The significance of Egger's test is set at 10% or less. The trim-and-fill method can infer the existence of unpublished hidden articles from a filled Funnel plot and correct the meta-analysis by imputing the presence of missing studies to yield an unbiased pooled estimate.[@b17-ott-9-1241] The aforementioned statistical analyses were completed with the Stata software release 12 (StataCorp, College Station, TX, USA).

Results
=======

Article selection
-----------------

After a careful literature retrieval and stringent eligibility appraisal, eleven out of 43 initially retrieved articles were included and summarized in this systematic review and meta-analysis.[@b9-ott-9-1241]--[@b11-ott-9-1241],[@b18-ott-9-1241]--[@b25-ott-9-1241] The PRISMA flowchart schematizing the selection of qualified studies is presented in [Figure 1](#f1-ott-9-1241){ref-type="fig"}. The total sample size was 4,446, including 2,074 breast cancer patients and 2,372 control subjects. Two studies conducted in different locations were reported by Menzel et al,[@b21-ott-9-1241] and they were handled separately, leading to a total of 12 studies in the final analysis.

Study characteristics
---------------------

[Table 1](#t1-ott-9-1241){ref-type="table"} shows the baseline characteristics of all included studies. Out of 12 independent studies, four were performed in Caucasians, three in Asians, and five in mixed-ethnic populations. Two studies were designed longitudinally and ten cross-sectionally. Of the 12 studies, six studies had controls collected from hospitals and six from populations. The RFLP genotyping method was adopted in seven studies. Breast cancer patients were slightly older than control subjects (54.95 vs 50.94 years, *P*=0.070). Mean BMI levels were comparable between the two groups (*P*\>0.999).

Overall estimates
-----------------

As the study by Mandelblatt et al[@b25-ott-9-1241] provided only ε4 positive/negative genotypes, overall allele comparisons were based on the remaining eleven studies ([Figure 2](#f2-ott-9-1241){ref-type="fig"}). In overall analyses, using the most common ε3 allele as reference, the ε2 (OR =0.87, 95% CI =0.72--1.05, *P*=0.154, *I*^2^=0.0%) and ε4 (OR =1.07, 95% CI =0.80--1.42, *P*=0.654, *I*^2^=71.8%) alleles were found not to be significantly associated with breast cancer risk in a random-effects model using the DerSimonian and Laird method. The probability of publication bias was low according to the Egger's test (for ε2 vs ε3, *P*=0.270, and for ε4 vs ε3, *P*=0.186); however, in the trim-and-fill method, three missing studies were filled for the comparison of alleles ε4 with ε3, in order to make the filled funnel plot symmetrical ([Figure 3](#f3-ott-9-1241){ref-type="fig"}). After taking these three studies into consideration, the odds of breast cancer conferred by ε4 allele was 0.90 (95% CI =0.68--1.20, *P*=0.487), with significant heterogeneity (*I*^2^=75.4%).

In addition, for the comparison of ε4 positive with ε4 negative genotypes, the odds of having breast cancer was 1.05 (95% CI =0.75--1.11, *P*=0.782) and heterogeneity was not significant (*I*^2^=46.1%) ([Figure S1](#SD1-ott-9-1241){ref-type="supplementary-material"}).

Stratified estimates
--------------------

To examine whether effect estimates were homogeneous in subgroups by race, study design, source of controls, genotyping method, and sample size, as well as whether heterogeneity is improved, a set of subgroup analyses were carried out in a random-effects model using the DerSimonian and Laird method ([Table 2](#t2-ott-9-1241){ref-type="table"}). By race, no significance was noted for the comparison of alleles ε2 with ε3 in Caucasians, Asians, and mixed-ethnic populations, while the comparison of alleles ε4 with ε3 was significant in Asians only (OR =1.58, 95% CI =1.17--6.32, *P*=0.003) without heterogeneity (*I*^2^=12.1%). Grouping studies by study design and source of controls revealed only marginal significance for the comparison of alleles ε4 with ε3 in hospital-based studies (OR =1.33, 95% CI =0.98--1.79, *P*=0.065, *I*^2^=30.2%). Similarly, studies with the RFLP genotyping method showed a significant effect estimate of 1.27 (95% CI =1.01--1.61, *P*=0.045, *I*^2^=34.3%) for the comparison of alleles ε4 with ε3. In contrast, the presence of ε2 was found to be significantly associated with breast cancer risk only in small studies (total sample size \<500) (OR =0.73, 95% CI =0.54--1.00, *P*=0.052) without heterogeneity (*I*^2^=0.0%).

Meta-regression analysis
------------------------

Two steps were taken by modeling potential confounders in a meta-regression analysis. First, potential confounders including age, BMI, race, study design, source of controls, genotyping method, and sample size were modeled one at a time, and unfortunately there was no indication of significance in all regression models. Second, age, BMI, race, study design, source of controls, genotyping method, and sample size were modeled altogether and still no significant confounding effects were observed (all *P*.0.05).

Discussion
==========

This is an updated systematic review and meta-analysis to assess the susceptibility of *APOE* gene ε2/ε3/ε4 polymorphism to breast cancer on the basis of eleven articles and 4,446 study subjects. Consistent with the meta-analytical results by Saadat,[@b12-ott-9-1241] we in a larger sample size observed a significant association between *APOE* gene ε4 allele and breast cancer risk in Asians. In addition, our findings in subgroup analyses suggest that source of controls, genotyping platform, and sample size might be potential causes of heterogeneity.

There were experimental data reporting a high expression level of *APOE* gene in many forms of cancer, including breast cancer.[@b11-ott-9-1241],[@b26-ott-9-1241] Elevated APOE level was postulated to trigger tumor growth by providing lipid substrates for tumor cells.[@b27-ott-9-1241] It was reported that different APOE isoforms affected tumor growth and proliferation at different levels, with ε2 allele having a largest protective effect, ε3 allele the moderate, and ε4 allele the least.[@b28-ott-9-1241] Consistent with this tendency, in overall analyses, we observed a reduced risk of breast cancer for ε2 allele and an increased risk for ε4 allele with reference to ε3 allele; yet no statistical significance was detected. However, after restricting the analysis to populations of Asian descent, the presence of ε4 allele remarkably rendered the study subjects 58% more likely to develop breast cancer, suggesting a race-specific role of *APOE* gene in breast carcinogenesis. Besides genetic makeup, lifestyle backgrounds such as physical activity and dietary habits could also account for this race-specific divergence. Due to the limitation of unavailable lifestyle data, there is always a possibility of residual confounding.

Heterogeneity is a potential issue when interpreting the results of all meta-analyses in medical literature.[@b29-ott-9-1241] In general, a meta-analysis can at least in part confirm the involvement of a genetic variant if heterogeneity is sufficiently recognized and taken into account. As revealed by our subgroup analyses, source of controls, genotyping platform, and sample size might be potential causes of heterogeneity. Taking source of controls as an example, it is widely believed that there is poor comparability between cases and controls in hospital-based studies given a regional specialty for the disease under study and differential hospitalization rates between cases and controls.[@b30-ott-9-1241] In contrast, study subjects drawn from a community or a general population might be representative of a true population. In view of this divergence, the results from population-based studies might be convincing. Moreover, sometimes genotyping errors can induce biases in frequency estimates for *APOE* gene ε2/ε3/ε4 polymorphism. For example, partial digestion of PCR product in RFLP genotyping method may introduce a misclassification bias, and it is essential to have RFLP images read independently by two persons. Further we know that individual studies with small sample sizes may have not sufficiently statistical power to detect a small effect and yield a fluctuated estimate, and often wide CIs may indicate lack of precision. On the basis of these observations, it is high time to confirm the findings of this systematic review and meta-analysis in more population-based, larger association studies with validated genotyping methods.

This systematic review and meta-analysis is limited due to the following aspects. First, only articles in English language are included, and a selection bias cannot be excluded, although no observable publication bias was recorded by the Egger's test. Second, only one polymorphism in *APOE* gene is analyzed and other polymorphisms in *APOE* gene and other susceptibility genes are not considered in this study, leading to the possibility that the potential role of *APOE* gene ε2/ε3/ε4 polymorphism is diluted or masked by other gene--gene and gene--environment interactions. Third, this systematic review and meta-analysis is not based on individual participant data and, therefore, adjusted effect-size estimates cannot be derived. Fourth, because mainly populations from Asia and Western countries were available, the present data did not allow us to extrapolate our findings to other racial or ethnic groups.

In conclusion, we in this updated systematic review and meta-analysis observed a significant association between *APOE* gene ε4 allele and breast cancer risk in Asians. Moreover, in our subgroup analyses, source of controls, genotyping platform, and sample size might be potential causes of heterogeneity. Further epidemiologic and functional validation is necessitated to provide a convincing effect estimate.

Supplementary material
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###### 

Forest plot of *APOE* gene ε4 positive genotypes relative to ε4 negative genotypes in overall analysis.

**Note:** Weights are from random effects analysis.

**Abbreviations:** OR, odds ratio; CI, confidence interval.
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**Abbreviation:** PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](ott-9-1241Fig1){#f1-ott-9-1241}

![Forest plots of *APOE* gene ε2 and ε4 alleles relative to ε3 allele in overall analyses.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](ott-9-1241Fig2){#f2-ott-9-1241}

![Filled funnel plots of *APOE* gene ε2 and ε4 alleles relative to ε3 allele in overall analyses.\
**Abbreviation:** SE, standard error of the mean.](ott-9-1241Fig3){#f3-ott-9-1241}

###### 

The baseline characteristics of study populations in this systematic review and meta-analysis

  Author (year)                            Race        Study design      Source of controls   Genotyping   Sample size   Age (years)   BMI (kg/m^2^)                 
  ---------------------------------------- ----------- ----------------- -------------------- ------------ ------------- ------------- --------------- ------ ------ ------
  Niemi et al[@b19-ott-9-1241]             Caucasian   Cross-sectional   Hospital             Others       211           299           55.2            43.3   25.9   25.2
  Moysich et al[@b18-ott-9-1241]           Caucasian   Cross-sectional   Population           RFLP         260           332           56.9            58     25.5   25.5
  Yaylim et al[@b20-ott-9-1241]            Mixed       Cross-sectional   Hospital             Others       32            20            56.9            54.3   NR     NR
  Menzel et al[@b21-ott-9-1241] (Prague)   Caucasian   Longitudinal      Population           Others       190           231           58              60     NR     NR
  Menzel et al[@b21-ott-9-1241] (Tyrol)    Caucasian   Cross-sectional   Population           Others       220           400           56              39     NR     NR
  Chang et al[@b22-ott-9-1241]             Asian       Cross-sectional   Population           RFLP         290           232           47.41           40.2   NR     NR
  Chang et al[@b23-ott-9-1241]             Asian       Cross-sectional   Hospital             RFLP         291           148           49.5            50.9   NR     NR
  Surekha et al[@b11-ott-9-1241]           Asian       Cross-sectional   Hospital             RFLP         110           110           47.6            47.6   NR     NR
  Porrata-Doria et al[@b10-ott-9-1241]     Mixed       Cross-sectional   Hospital             RFLP         205           229           NR              NR     NR     NR
  McDonald et al[@b24-ott-9-1241]          Mixed       Cross-sectional   Hospital             RFLP         54            24            51.15           47     NR     NR
  Cibeira et al[@b9-ott-9-1241]            Mixed       Longitudinal      Population           RFLP         47            165           57.6            56.1   28.2   28.9
  Mandelblatt et al[@b25-ott-9-1241]       Mixed       Cross-sectional   Population           Others       164           182           68.2            67.3   NR     NR

  ---------------------------------------- -- ---- ----- ----- ---- ----- ----- ----- ---- ----- ----
                                                                                                 
  Niemi et al[@b19-ott-9-1241]                17   331   74    22   466   109   NR    NR   NR    NR
  Moysich et al[@b18-ott-9-1241]              34   424   62    43   533   88    201   59   251   81
  Yaylim et al[@b20-ott-9-1241]               2    61    1     0    40    0     31    1    20    0
  Menzel et al[@b21-ott-9-1241] (Prague)      15   156   17    27   237   36    NR    NR   NR    NR
  Menzel et al[@b21-ott-9-1241] (Tyrol)       31   337   64    53   449   176   NR    NR   NR    NR
  Chang et al[@b22-ott-9-1241]                56   410   114   45   349   70    NR    NR   NR    NR
  Chang et al[@b23-ott-9-1241]                34   496   52    24   256   16    NR    NR   NR    NR
  Surekha et al[@b11-ott-9-1241]              6    193   21    11   201   8     90    20   102   8
  Porrata-Doria et al[@b10-ott-9-1241]        13   345   52    21   392   48    156   49   184   46
  McDonald et al[@b24-ott-9-1241]             9    80    19    3    39    6     NR    NR   NR    NR
  Cibeira et al[@b9-ott-9-1241]               4    72    18    33   238   59    32    15   107   58
  Mandelblatt et al[@b25-ott-9-1241]          NR   NR    NR    NR   NR    NR    256   60   131   43
  ---------------------------------------- -- ---- ----- ----- ---- ----- ----- ----- ---- ----- ----

**Abbreviations:** BMI, body mass index; RFLP, restriction fragment length polymorphism; NR, not reported.

###### 

Subgroup analyses of *APOE* gene ε2 and ε4 alleles relative to ε3 allele on breast cancer risk

  Subgroups                Number of studies   ε2 vs ε3   ε4 vs ε3                                                                 
  ------------------------ ------------------- ---------- ------------ ------- ------- ------- ------ ------------ ------- ------- -------
  Race                                                                                 0.149                                       0.968
   Caucasian               4                   0.91       0.69--1.19   0.472   0.0%            0.74   0.52--1.04   0.086   70.4%   
   Asian                   3                   0.88       0.64--1.21   0.430   0.0%            1.58   1.17--6.32   0.003   12.1%   
   Mixed                   4                   0.72       0.41--1.26   0.252   4.6%            1.19   0.87--1.65   0.280   0.0%    
  Study design                                                                         0.132                                       0.869
   Cross-sectional         9                   0.90       0.73--1.10   0.296   0.0%            1.13   0.81--1.59   0.472   76.8%   
   Longitudinal            2                   0.66       0.33--1.32   0.236   26.0%           0.86   0.56--1.31   0.472   0.0%    
  Source of controls                                                                   0.227                                       0.888
   Hospital-based          6                   0.83       0.60--1.15   0.255   0.0%            1.33   0.98--1.79   0.065   30.2%   
   Population-based        5                   0.89       0.71--1.13   0.349   0.0%            0.84   0.55--1.28   0.428   80.9%   
  Genotyping method                                                                    0.189                                       0.349
   RFLP                    7                   0.87       0.68--1.10   0.230   0.0%            1.27   1.01--1.61   0.045   34.3%   
   Others                  4                   0.88       0.63--1.22   0.438   0.0%            0.70   0.45--1.10   0.125   66.5%   
  Total sample size                                                                    0.094                                       0.426
   ≥500 (large studies)    4                   0.96       0.76--1.23   0.760   0.0%            0.87   0.56--1.34   0.523   85.6%   
   \>500 (small studies)   7                   0.73       0.54--1.00   0.052   0.0%            1.28   0.94--1.73   0.118   27.5%   

**Abbreviations:** OR, odds ratio; CI, confidence interval; *P*~reg~, *P*-value from meta-regression analysis; RFLP, restriction fragment length polymorphism.
